DE60238674D1 - Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid - Google Patents

Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid

Info

Publication number
DE60238674D1
DE60238674D1 DE60238674T DE60238674T DE60238674D1 DE 60238674 D1 DE60238674 D1 DE 60238674D1 DE 60238674 T DE60238674 T DE 60238674T DE 60238674 T DE60238674 T DE 60238674T DE 60238674 D1 DE60238674 D1 DE 60238674D1
Authority
DE
Germany
Prior art keywords
tetrahydrofuro
oxopyrrolidin
acetamide
dimethyl
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238674T
Other languages
English (en)
Inventor
Haruko Yamabe
Takayuki Ishige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60238674D1 publication Critical patent/DE60238674D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60238674T 2001-04-19 2002-04-19 Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid Expired - Lifetime DE60238674D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001121681 2001-04-19
JP2001121682 2001-04-19
PCT/JP2002/003916 WO2002085910A1 (en) 2001-04-19 2002-04-19 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide

Publications (1)

Publication Number Publication Date
DE60238674D1 true DE60238674D1 (de) 2011-02-03

Family

ID=26613875

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238674T Expired - Lifetime DE60238674D1 (de) 2001-04-19 2002-04-19 Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid

Country Status (11)

Country Link
US (1) US6884805B2 (de)
EP (1) EP1392696B1 (de)
JP (1) JP2004525985A (de)
KR (1) KR100909923B1 (de)
CN (1) CN100484939C (de)
AT (1) ATE492549T1 (de)
CA (1) CA2439117C (de)
DE (1) DE60238674D1 (de)
HK (1) HK1061564A1 (de)
TW (1) TWI332503B (de)
WO (1) WO2002085910A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598674B2 (ja) * 2003-01-08 2010-12-15 田辺三菱製薬株式会社 統合失調症治療剤
EP1986647A4 (de) 2006-02-07 2009-09-02 Mitsubishi Tanabe Pharma Corp Durch 4-acylaminopyridin-derivate vermittelte neurogenese
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative

Also Published As

Publication number Publication date
CN100484939C (zh) 2009-05-06
KR100909923B1 (ko) 2009-07-29
US6884805B2 (en) 2005-04-26
WO2002085910A1 (en) 2002-10-31
EP1392696B1 (de) 2010-12-22
CA2439117A1 (en) 2002-10-31
TWI332503B (en) 2010-11-01
US20040122034A1 (en) 2004-06-24
JP2004525985A (ja) 2004-08-26
EP1392696A1 (de) 2004-03-03
CA2439117C (en) 2011-02-08
ATE492549T1 (de) 2011-01-15
KR20030097833A (ko) 2003-12-31
CN1498219A (zh) 2004-05-19
HK1061564A1 (en) 2004-09-24

Similar Documents

Publication Publication Date Title
NO903851L (no) Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
BR1100086A (pt) Derivados de fluoralcóxibenzilamino de heterocìclos contendo nitrogênio
HUP0400240A2 (hu) Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények
DK0675886T3 (da) Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
ES2071334T3 (es) Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
DE60137364D1 (de) Kristalline formen von atorvastatin
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
NO963370D0 (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NO941884L (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
FI940229A0 (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
ATE313539T1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
DK0775118T3 (da) Benzimidazolderivater, der har dopaminerg aktivitet
DE60238674D1 (de) Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére
FI905957A0 (fi) Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet.
NO934758L (no) Alkylsubstituerte heterosykliske forbindelser
ATE109139T1 (de) Mittel zum schutz von pflanzen gegen krankheiten.
PT703232E (pt) Derivados do 2,3-di-hidro-1h-isoindole processo para a sua preparacao e o seu uso como inibidores da reassimilacao da serotonina
NO20021950D0 (no) Fremgangsmåte for fremstilling av N-(4,5-bis-metansulfonyl-2- metylbenzoyl)-guanidin-hydroklorid
ES2186369T3 (es) Imidazotriazolopirimidinas en calidad de medicamentos con efecto antagonista de adenosina.
TR200402685T4 (tr) Merkezi sinir sistemi üzerine etki eden siklobüta-indol karboksamid türevleri, bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler.
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
TH21983A (th) อนุพันธ์ของควิโนลีน (2)